The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.

The first biosimilar product filgrastim-sndz was approved by the FDA in 2015, but real-world evaluations of its uptake and cost in nationally representative populations are limited.

For two drugs with a branded product that had a large price increase, the market share of the related biosimilar or generic was higher among Medicaid MCOs not subject to preferred drug lists (PDLs) as compared to MCOs subject to PDLs and Medicaid FFS programs, according to a JMCP study.

This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval surveillance of biologics and biosimilars by utilizing its distributed research network.

This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval survellience of biologics and biosimilars by utilizing its distributed research network.

AMCP webinar that provided an overview of the current state of biosimilars in the US, description of some barriers to utilization, discussion of real-world data and how stakeholders may use real-world evidence to inform treatment and coverage decisions, and an update on the efforts of BBCIC.

Findings from this review indicate that health care providers approach biosimilars with caution due to limited knowledge, low prescribing comfort, and concerns over safety and efficacy. The authors of this JMCP article recommend clinician-directed education to realize the full cost-saving potential of biosimilars.